Opinion|Videos|January 6, 2025
Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
Author(s)Robert M. Rifkin, MD, FACP
Robert M. Rifkin, MD, FACP, discusses how the MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition sheds light on elranatamab’s role in relapsed/refractory multiple myeloma while panelists discuss how emerging data on bispecific antibodies and combination strategies could shape treatment timing and improve outcomes, especially in heavily pretreated patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition provided critical insights into elranatamab for patients with relapsed/refractory multiple myeloma. What are your key takeaways from this update, and how do these data influence the role of elranatamab in the current treatment paradigm?
- With growing data on bispecifics, what are your perspectives on the ideal timing for integrating these therapies into treatment plans, especially in heavily pretreated patients vs earlier lines?
- There is increasing interest in combining bispecific antibodies with other therapies. Which combination strategies do you find most promising, and what potential do they hold for enhancing outcomes in relapsed/refractory multiple myeloma?
Advertisement
Related to this article
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5